Insider transactions

EDGAR

Edgewise Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
34 transactions, 485,784.00 shares
Sum of shares × price per share: 17,630,730.3316

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 105

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-16 Filed 2026-11-18Donovan Joanne M. Officer: CMO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)854.0045.48
38,839.92

Derived: shares × price per share. Exact value 38839.9200.

8,139.00Direct (D) Yes
F1, F2
  • F1 The shares were acquired through a purchase under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2025.
  • F2 Includes 368 shares purchased on November 16, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
Open filing 0001644087-26-000007 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10Nofi Michael Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)10,937.000.00
0

Derived: shares × price per share. Exact value 0.0000.

10,937.00Direct (D) No— Open filing 0001705477-26-000003 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10Nofi Michael Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,442.0045.427
201,786.734

Derived: shares × price per share. Exact value 201786.73400.

6,495.00Direct (D) No
F1, F2
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person
  • F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001705477-26-000003 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10Nofi Michael Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (10,937.00) — exercise price 0.00
Disposed (D)10,937.000.00
0

Derived: shares × price per share. Exact value 0.0000.

32,813.00Direct (D) No
F3
  • F3 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.
Open filing 0001705477-26-000003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02Fox Jonathan C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)308.000.00
0

Derived: shares × price per share. Exact value 0.0000.

25,141.00Direct (D) No— Open filing 0001655016-26-000006 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Donovan Joanne M. Officer: CMO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,919.0043.4065
126,703.5735

Derived: shares × price per share. Exact value 126703.573500.

8,625.00Direct (D) No
F7, F8
  • F7 The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
  • F8 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001644087-26-000005 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-17MOORE JOHN R Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000.00) — exercise price 43.56
Acquired (A)65,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

65,000.00Direct (D) No
F1
  • F1 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001191702-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-17Derakhshan Behrad Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (100,000.00) — exercise price 43.56
Acquired (A)100,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

100,000.00Direct (D) No
F1
  • F1 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001853109-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-17Nofi Michael Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (48,750.00) — exercise price 43.56
Acquired (A)48,750.000.00
0

Derived: shares × price per share. Exact value 0.0000.

48,750.00Direct (D) No
F1
  • F1 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001705477-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-17Donovan Joanne M. Officer: CMO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000.00) — exercise price 43.56
Acquired (A)65,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

65,000.00Direct (D) No
F1
  • F1 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001644087-26-000006 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-17Russell Alan J Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000.00) — exercise price 43.56
Acquired (A)65,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

65,000.00Direct (D) No
F1
  • F1 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001853529-26-000003 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,781.000.00
0

Derived: shares × price per share. Exact value 0.0000.

30,336.00Direct (D) No— Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,031.000.00
0

Derived: shares × price per share. Exact value 0.0000.

37,367.00Direct (D) No— Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,238.0043.6775
141,427.745

Derived: shares × price per share. Exact value 141427.745000.

34,129.00Direct (D) No
F1, F2
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,273.0043.6759
99,275.3207

Derived: shares × price per share. Exact value 99275.320700.

31,856.00Direct (D) No
F1, F3
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.32 to $44.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)390.0044.46
17,339.4

Derived: shares × price per share. Exact value 17339.4000.

31,466.00Direct (D) No
F1
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,781.00) — exercise price 0.00
Disposed (D)5,781.000.00
0

Derived: shares × price per share. Exact value 0.0000.

11,563.00Direct (D) No
F4
  • F4 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (7,031.00) — exercise price 0.00
Disposed (D)7,031.000.00
0

Derived: shares × price per share. Exact value 0.0000.

21,094.00Direct (D) No
F5
  • F5 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (32,500.00) — exercise price 0.00
Acquired (A)32,500.000.00
0

Derived: shares × price per share. Exact value 0.0000.

32,500.00Direct (D) No
F6
  • F6 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Russell Alan J Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000.00) — exercise price 0.00
Acquired (A)65,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

65,000.00Direct (D) No
F7
  • F7 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001853529-26-000002 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,781.000.00
0

Derived: shares × price per share. Exact value 0.0000.

29,426.00Direct (D) No— Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,500.000.00
0

Derived: shares × price per share. Exact value 0.0000.

36,926.00Direct (D) No— Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,171.0043.7934
95,075.4714

Derived: shares × price per share. Exact value 95075.471400.

34,755.00Direct (D) No
F1, F2
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.30 to $44.145, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)304.0044.5018
13,528.5472

Derived: shares × price per share. Exact value 13528.547200.

34,451.00Direct (D) No
F1, F3
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.47 to $44.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)150.0044.4433
6,666.495

Derived: shares × price per share. Exact value 6666.495000.

34,301.00Direct (D) No
F1, F4
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.415 to $44.50, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,475.0043.6984
108,153.54

Derived: shares × price per share. Exact value 108153.540000.

31,826.00Direct (D) No
F1, F5
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F5 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,781.00) — exercise price 0.00
Disposed (D)5,781.000.00
0

Derived: shares × price per share. Exact value 0.0000.

11,563.00Direct (D) No
F6
  • F6 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (7,500.00) — exercise price 0.00
Disposed (D)7,500.000.00
0

Derived: shares × price per share. Exact value 0.0000.

22,500.00Direct (D) No
F7
  • F7 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (50,000.00) — exercise price 0.00
Acquired (A)50,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

50,000.00Direct (D) No
F8
  • F8 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Derakhshan Behrad Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (100,000.00) — exercise price 0.00
Acquired (A)100,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

100,000.00Direct (D) No
F9
  • F9 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001853109-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Nofi Michael Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (24,375.00) — exercise price 0.00
Acquired (A)24,375.000.00
0

Derived: shares × price per share. Exact value 0.0000.

24,375.00Direct (D) No
F1
  • F1 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
Open filing 0001705477-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Nofi Michael Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (48,750.00) — exercise price 0.00
Acquired (A)48,750.000.00
0

Derived: shares × price per share. Exact value 0.0000.

48,750.00Direct (D) No
F2
  • F2 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001705477-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,781.000.00
0

Derived: shares × price per share. Exact value 0.0000.

15,995.00Direct (D) No— Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,718.000.00
0

Derived: shares × price per share. Exact value 0.0000.

22,713.00Direct (D) No— Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,439.0043.8081
106,847.9559

Derived: shares × price per share. Exact value 106847.955900.

20,274.00Direct (D) No
F1, F2
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)59.0044.4142
2,620.4378

Derived: shares × price per share. Exact value 2620.437800.

20,215.00Direct (D) No
F1, F3
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.42, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)99.0044.5019
4,405.6881

Derived: shares × price per share. Exact value 4405.688100.

20,116.00Direct (D) No
F1, F4
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $44.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,419.0043.7985
105,948.5715

Derived: shares × price per share. Exact value 105948.571500.

17,697.00Direct (D) No
F1, F5
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person.
  • F5 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,781.00) — exercise price 0.00
Disposed (D)5,781.000.00
0

Derived: shares × price per share. Exact value 0.0000.

11,563.00Direct (D) No
F6
  • F6 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (6,718.00) — exercise price 0.00
Disposed (D)6,718.000.00
0

Derived: shares × price per share. Exact value 0.0000.

20,157.00Direct (D) No
F7
  • F7 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (32,500.00) — exercise price 0.00
Acquired (A)32,500.000.00
0

Derived: shares × price per share. Exact value 0.0000.

32,500.00Direct (D) No
F8
  • F8 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14MOORE JOHN R Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000.00) — exercise price 0.00
Acquired (A)65,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

65,000.00Direct (D) No
F9
  • F9 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open filing 0001191702-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)17,969.000.00
0

Derived: shares × price per share. Exact value 0.0000.

48,584.00Direct (D) No— Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)21,875.000.00
0

Derived: shares × price per share. Exact value 0.0000.

70,459.00Direct (D) No— Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,782.0043.6408
383,253.5056

Derived: shares × price per share. Exact value 383253.505600.

61,677.00Direct (D) No
F1, F2
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person
  • F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,276.0043.6582
361,315.2632

Derived: shares × price per share. Exact value 361315.263200.

53,401.00Direct (D) No
F1, F3
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person
  • F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)913.0044.33
40,473.29

Derived: shares × price per share. Exact value 40473.2900.

52,488.00Direct (D) No
F1, F4
  • F1 Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary sale by the Reporting Person
  • F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (17,969.00) — exercise price 0.00
Disposed (D)17,969.000.00
0

Derived: shares × price per share. Exact value 0.0000.

35,938.00Direct (D) No
F5
  • F5 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (21,875.00) — exercise price 0.00
Disposed (D)21,875.000.00
0

Derived: shares × price per share. Exact value 0.0000.

65,625.00Direct (D) No
F6
  • F6 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14KOCH KEVIN Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (100,000.00) — exercise price 0.00
Acquired (A)100,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

100,000.00Direct (D) No
F7
  • F7 Restricted Stock Units (RSUs) granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
Open filing 0001185829-26-000001 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
JANUS HENDERSON GROUP Ltd. Common Stock6.77,298,52109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001274173-26-000238 Dispute this row
FMR LLC COMMON STOCK0.9970,920.0009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002741 Dispute this row
Abigail P. Johnson COMMON STOCK0.9970,920.0009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002741 Dispute this row
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share9.510,215,455.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097206 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share9.510,215,455.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097206 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share9.510,215,455.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097206 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share8.38,961,631.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097206 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share7.88,392,730.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000922 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share7.88,392,730.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000922 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share7.88,392,730.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000922 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share7.88,392,730.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000922 Dispute this row
Baker Bros. Advisors LP Common Stock, par value $0.0001 per share3.43,701,719.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097041 Dispute this row
Baker Bros. Advisors (GP) LLC Common Stock, par value $0.0001 per share3.43,701,719.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097041 Dispute this row
Julian C. Baker Common Stock, par value $0.0001 per share3.43,701,719.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097041 Dispute this row
Felix J. Baker Common Stock, par value $0.0001 per share3.43,701,719.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097041 Dispute this row
FMR LLC COMMON STOCK5.15,489,135.0006/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0000315066-26-001979 Dispute this row
Abigail P. Johnson COMMON STOCK5.15,489,135.0006/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0000315066-26-001979 Dispute this row
Novo Holdings A/S Common Stock, par value $0.0001 per share4.95,350,000.0004/23/2026 Filed 2026-04-27SCHEDULE 13D/AAmendment 6Open filing 0001388325-26-000014 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock5.55,915,55603/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001274173-26-000124 Dispute this row
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share6.26,541,210.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-016362 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share6.26,541,210.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-016362 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share6.26,541,210.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-016362 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share5.55,778,924.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-016362 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock4.74,979,33109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001274173-25-000268 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share9.910,428,437.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-25-000488 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share9.910,428,437.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-25-000488 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share9.910,428,437.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-25-000488 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share9.910,428,437.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-25-000488 Dispute this row
Baker Bros. Advisors LP Common Stock, par value $0.0001 per share6.97,305,940.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-078659 Dispute this row
Baker Bros. Advisors (GP) LLC Common Stock, par value $0.0001 per share6.97,305,940.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-078659 Dispute this row
Julian C. Baker Common Stock, par value $0.0001 per share6.97,305,940.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-078659 Dispute this row
Felix J. Baker Common Stock, par value $0.0001 per share6.97,305,940.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-078659 Dispute this row
Perceptive Advisors LLC Common Stock, par value $0.0001 per share4.44,639,94906/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 2Open filing 0000950170-25-108936 Dispute this row
Joseph Edelman Common Stock, par value $0.0001 per share4.44,639,94906/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 2Open filing 0000950170-25-108936 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, par value $0.0001 per share4.44,639,94906/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 2Open filing 0000950170-25-108936 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock5.25,503,34906/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 2Open filing 0001274173-25-000244 Dispute this row
BlackRock, Inc. Common Stock5.55,824,86606/30/2025 Filed 2025-07-17SCHEDULE 13G/AAmendment 1Open filing 0002052113-25-003023 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,687,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Edgewise Therapeutics, Inc.